CNTB Stock Forecast & Price Target

Connect Biopharma Hldgs is a clinical-stage biopharmaceutical company with a promising drug candidate, rademikibart, targeting a high unmet need population in the treatment of asthma and COPD. The drug has potential for use in other conditions, but competition from established treatments may impact its commercial success. The company's focus on the acute setting, with potential for future use in chronic conditions, coupled with its exploration of combination treatments, makes it an attractive investment prospect.

Connect Biopharma Hldgs is a high-risk investment due to its focus on a single drug, rademikibart, and the lack of significant results from its phase 1 and 2 clinical studies. Additionally, the company's strategy of pursuing both acute and chronic indications in parallel may prove to be challenging and costly. Furthermore, the potential for hyper-eosinophilia associated with the approved drug, Dupixent, could also pose a risk to the success of rademikibart.